Leber Congenital Amaurosis (LCA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Leber congenital amaurosis (LCA) is a vision disorder that primarily impacts the retina, the specialized tissue at the rear of the eye responsible for light and color detection. LCA can arise from mutations in a minimum of 14 genes, all essential for normal vision. The primary culprits behind this disorder are mutations in the CEP290, CRB1, GUCY2D, and RPE65 genes, while other gene mutations account for a smaller portion of cases. In uncommon instances, LCA is inherited as an autosomal dominant genetic condition. Presently, mutations in three genes, CRX, IMPDH1, and OTX2, are linked to this type of LCA. LCA is marked by a significant decline in visual acuity (equal to or less than 20/400) or blindness within the first year of life. Depending on the genetic basis, symptoms may include sluggish pupillary responses, wandering eye movements, sensitivity to light, high hyperopia, nystagmus, convergent strabismus, or keratoconus. A distinctive sign known as Franceschetti's oculo-digital sign, characterized by eye poking, pressing, and rubbing, is a defining feature. LCA can also be associated with gene mutations related to syndromes featuring neurodevelopmental delay, intellectual impairment, oculomotor apraxia-like difficulties in eye movement, and kidney dysfunction. The FDA has approved Voretigene neparvovec-rzyl (LuxturnaTM) to treat Leber congenital amaurosis (LCA). This marks a groundbreaking milestone as it is the first gene therapy approved by the FDA to address a disease. The treatment involves injecting a new, functional gene copy under the retina to target the appropriate cells.

·       Leber congenital amaurosis affects 2 to 3 newborns out of every 100,000. It's one of the most common causes of childhood blindness.

 

Thelansis’s “Leber Congenital Amaurosis (LCA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leber Congenital Amaurosis (LCA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Leber Congenital Amaurosis (LCA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Leber Congenital Amaurosis (LCA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Leber Congenital Amaurosis (LCA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Leber Congenital Amaurosis (LCA), Leber Congenital Amaurosis (LCA) market outlook, Leber Congenital Amaurosis (LCA) competitive landscape, Leber Congenital Amaurosis (LCA) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)